Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANNX vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FDMT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

FDMT Overall Winner 6-Pillar Tally: ANNX 2 – 3 FDMT (1 Tie) Matrix Metrics: ANNX 4 – 4 FDMT

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.58 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANNX vs FDMT
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.58
-8.55% 1D
Market Cap $757.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.68β · 62% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 42.0 Fund 54.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $3.98 · SMA50: $4.00
FDMT NASDAQ Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (ANNX 2 – 3 FDMT)

Columns: Metric · ANNX · FDMT
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +0.0% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $96M
Market Cap $757.3M $669.3M
3. Profitability & Quality ANNX
Gross Margin N/A N/A
Operating Margin 0.0% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -130.8% -56.7%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$190M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $29M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 209.2% (40th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.75x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANNX (4) vs FDMT (4)
Institutional Metric ANNX FDMT Criterion Row Edge
Market Capitalization
Scale
$757.3M $669.3M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
0.0% -222.7% Higher Margin ANNX
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-130.8% -56.7% Higher ROE FDMT
52-Week Range Position
Momentum
22% ($3–$7) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.68β · 62% Vol 1.89β · 90% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
N/A $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$190M ($29M Net Cash) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +9.17 pp
ANNX: +5.13% · FDMT: -4.04%
3M Horizon FDMT +11.24 pp
ANNX: -32.1% · FDMT: -20.86%
6M Horizon FDMT +66.99 pp
ANNX: -27.72% · FDMT: +39.27%
1Y Horizon ANNX +20.44 pp
ANNX: +33.77% · FDMT: +13.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs FDMT. Trailing 12-month operating profitability (ANNX 0.0% vs FDMT -222.7%) and valuation multiples (ANNX N/M vs FDMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M
FDMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$96M
Gross MarginN/A
Op. Margin-222.7%
ROE / Fwd P/E-56.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANNX BREAKDOWN
87d in phase · OBV DISTRIBUTION
Current IV 209.2%
IV Percentile 40th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $757.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANNX vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.58 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus $96M for FDMT. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

FDMT screens cheaper on headline valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANNX carries 209.2% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 62% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.